---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011873"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:45:35.194375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025

## Summary
- Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.
- Topline data from STAR-2 expected H1 2027; patients can rollover into 9-month extension study.
- NDA filing for XYNGARI anticipated in H1 2028 after extension study completion by end of Q4 2027.

## SEC filing metadata
- accession: 0001641172-25-011873
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/0001641172-25-011873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011873
- JSON: https://secwatch.observer/filing/0001641172-25-011873.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.